Pacific Biosciences of California, Inc., commonly known as PacBio, is a leading biotechnology company headquartered in Menlo Park, California, USA. Founded in 2004, PacBio has established itself as a pioneer in the field of genomic sequencing, particularly with its innovative Single Molecule, Real-Time (SMRT) sequencing technology. This cutting-edge approach allows for highly accurate and long-read DNA sequencing, setting it apart from traditional methods. With a strong presence in the genomics industry, PacBio serves a diverse range of sectors, including academic research, clinical diagnostics, and agricultural genomics. The company has achieved significant milestones, including the launch of its Sequel II and Sequel IIe systems, which have enhanced the accessibility and efficiency of genomic analysis. Recognised for its contributions to advancing genomic research, PacBio continues to solidify its market position as a trusted provider of high-quality sequencing solutions.
How does Pacific Biosciences of California, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pacific Biosciences of California, Inc.'s score of 25 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pacific Biosciences of California, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company has not established documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there is no available data on their emissions or reduction initiatives, it is unclear how Pacific Biosciences is addressing climate change or its carbon footprint. The lack of reported emissions and targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, making it essential for Pacific Biosciences to consider establishing measurable targets and reporting frameworks to align with industry standards and stakeholder expectations.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pacific Biosciences of California, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.